Form 4: Aadi Bioscience Executive Chairman Neil Desai Sells Shares

Neil Desai, Executive Chairman of Aadi Bioscience, sold shares of the company's common stock on June 3rd and 4th, 2024, according to a Form 4 filing with the SEC.

Summary

• Neil Desai, the Executive Chairman of Aadi Bioscience, sold 19,775 shares of common stock on June 3, 2024, at a weighted average price of $1.8086.
• He also sold 20,225 shares on June 4, 2024, at a weighted average price of $1.7674.
• These sales were executed under a Rule 10b5-1 trading plan.
• Following these transactions, Desai directly owns no shares, but indirectly owns 1,291,543 shares through the Anishka Family Trust and 639,698 shares through the Anishka Irrevocable 2016 Trust.
• Desai is the trustee of the Anishka Family Trust and disclaims beneficial ownership of the shares held by the Anishka Irrevocable 2016 Trust except to the extent of any pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral sentiment as the stock sales were conducted under a pre-arranged trading plan, mitigating concerns about insider information influencing the decision.

Negatives

• The Executive Chairman selling shares could be perceived negatively by investors.

Risks

• Executive stock sales can sometimes signal a lack of confidence in the company's future performance, although this sale was executed under a pre-arranged trading plan.

Industry Context

Insider trading activity is always closely watched by investors as it can provide signals, though often noisy, about management's view of the company's prospects. However, sales under 10b5-1 plans are less informative.

Stakeholder Impact

• Shareholders may react to the news of the Executive Chairman selling shares, although the impact is likely to be limited due to the pre-arranged trading plan.

Key Dates